Puma Biotechnology

PBYI

Market cap $324M

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted to December 2025 new hires, in accordance with Nasdaq Listing Rule 5635(c)(4).

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on Dec. 19, 2025.

CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award.

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 11,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awa.

Puma Biotechnology, Inc. ( PBYI ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber Roger Storms Maximo F. Nougues - CFO & Principal Accounting Officer Conference Call Participants Marc Frahm - TD Cowen, Research Division Presentation Operator Good afternoon.

Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.

Puma Biotech (PBYI) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.45 per share a year ago.